TWIST1 and non-small cell lung carcinoma: Based on the results outlined above, we propose that MEOX2 and TWIST1 overexpression is associated with reduced H3K27me3 levels and that increased H3K4me3 levels at both the MEOX2 and TWIST1 promoters participate in resistance to oncologic drugs, as likely occurred in cisplatinum/carboplatinum-treated NSCLC patients (Table 1).